糖尿病管理中的替代治疗策略
Alessia Annicchiarico1, Barbara Barile1, Cinzia Buccoliero1
1Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Bari 70125, Italy.
World journal of diabetes
|July 10, 2024
概括
新的糖尿病治疗探索干细胞和生物材料,以改善胰岛素的可用性和管理并发症. 这些先进的策略旨在克服诸如小岛移植等当前治疗方法的局限性,为更好的糖尿病管理提供希望.
科学领域:
- 内分泌学和代谢性疾病.
- 再生医学是一种再生医学.
- 细胞疗法细胞疗法
背景情况:
- 糖尿病是一种代谢障碍,因胰腺β细胞功能障碍或胰岛素抵抗而导致高血糖症.
- 目前的治疗包括胰岛素治疗,营养和体育活动,在严重病例中选择岛屿移植.
- 岛屿/胰腺可用性的限制需要探索替代治疗策略.
研究的目的:
- 审查超越传统方法的糖尿病管理的新型治疗策略.
- 评估基于干细胞的疗法和生物材料应用在糖尿病治疗中的潜力.
- 突出目前的局限性和先进糖尿病管理的未来方向.
主要方法:
- 关于胰岛移植,介质干细胞 (MSC) 和糖尿病诱导多能干细胞 (iPSC) 的现有文献的综述.
- 分析涉及MSC与小岛的共同移植以及生物材料/支架用于细胞输送的策略.
- 讨论作用机制,包括外体释放和保护对炎症因素的保护.
主要成果:
- 小岛移植可以改善糖尿病并发症,改善生活质量和生存率,但面临着可用性挑战.
- 将MSC与小岛共同移植显示出希望,通过诸如外体细胞释放等机制提供保护.
- 植入MSC证明了糖尿病相关并发症的好处,例如伤口愈合,通过生物材料进行增强的输送.
结论:
- 干细胞疗法,特别是MSC和iPSC,代表了糖尿病管理的有希望的替代策略.
- 基于生物材料的输送系统正在提高细胞疗法的疗效.
- 需要进一步的研究来克服局限性,并优化这些新的方法,以广泛的临床应用.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
01:22Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:24Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
01:29Chronic Pancreatitis II: Collaborative Care
84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
84